Improvement of the Patientenadherence and avoidance of side effects by one special speech hour for oral tumour therapy

Not Applicable

Conditions: C83.1
C91.1
PATIENTENADHERENCE QUALITY OF LIFE CURVESTOXICITYCURVE NCI CTC Version 4.0 HOSPITALISATIONS DOCTOR'S CONTACTS
C18
C19
C20
C50
C34
C64
C43

Registration Number: DRKS00010797

Lead Sponsor: Onkologisch-palliativmedizinisches Netzwerk Landshut

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 100

Inclusion Criteria

inclusion criteria
All patients in whom a secured hematologic or oncologic disease following entity exists and which are treated with an oral anti-proliferative therapy :
Colorektaleskarzinom
breast cancer
Non small cell lung cancer ( adenocarcinoma )
Renal Cell Carcinoma
Malignant melanoma
Mantle cell lymphoma
Chronic Lymphocytic Leukemia
follicular lymphoma
multiple myeloma
Primary myelofibrosis
polycythemia vera
Chronic myeloid leukemia
Written informed consent
Age = 18 years
Ability to work independently tablets
An adequate knowledge
Legal capacity
Estimated life expectancy = 3 months
ECOG performance status 0-2

Exclusion Criteria

Lack of ability to independently tablets

Lack of knowledge of German or lack of ability to autonomously understand and fill out the applications described in the study questionnaires

Missing or limited legal capacity

Participation in another clinical trial with not yet approved substances

Any significant concomitant disease that excludes the participation of the patient in the study of the investigator 's opinion

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary study endpoints<br>The following parameters are compared for differences in membership of the cohorts ( routine medical check vs. co-supervision by a specialist for oral and subcutaneous tumor therapy ) :<br>adherence all 3 months<br>Query on adherence questionnaire<br>Independent verification of the drugs taken on the basis of brought Blister (study - nurses )<br>patient safety all 3 months<br>Detection of adverse reactions by CTCAE v4.03 criteria<br>patient satisfaction<br>Query by standardized questionnaire<br>time<br>Duration of examination / training talks<br>Waiting times for consultation

Secondary Outcome Measures